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The present and future crossmatch 
The crossmatch has been used as the final phase of 
pretransfusion testing for over half a century.’ However, 
during this time, there have been frequent modifications 
of the procedure, as well as differences of opinion as to 
the extent of its performance. In recent years, modifi- 
cations have focused on its abbreviation. 
When the American Association of Blood Banks first 
published its standards in 1958, the crossmatch was de- 
scribed in relatively broad terms. The major crossmatch 
was specifically required, while the minor crossmatch 
was characterized as an optional test. The latter never 
has been a required procedure, although the tendency of 
many transfusionists to “wear a belt with their suspen- 
ders,, was illustrated by their reluctance to part with 
In addition, the major crossmatch was mandated to in- 
clude two methods: one to demonstrate “serum or saline 
active” antibodies and the other to detect “incomplete 
or blocking” antibodies. An appendix to that edition of 
the standards specified the use of albumin and the in- 
direct antiglobulin test. It must be recalled that this edi- 
tion predated the general adoption of pretransfusion 
screening for unexpected antibodies in recipient serum, 
a procedure that had been introduced almost a decade 
b e f ~ r e . ~  
By 1962, the standards declared that the antiglobulin 
phase of the crossmatch was optional, depending upon 
its inclusion in the antibody screening test. This seem- 
ingly casual approach was solidified in the 1970 edition, 
as demonstration of “agglutinating and coating antibod- 
ies,, was required, as was performance of an antiglob- 
ulin test. The pendulum then swung to a more permissive 
approach to the crossmatch so that, first, only “signif- 
icant’, and later, “clinically significant” antibodies had 
to be detected. By 1984, the requirement for routine use 
of an antiglobulin test was rescinded unless “clinically 
significant unexpected antibodies were detectable” in 
the patient’s serum. 
This change was based on a philosophical modifica- 
tion of the test’s purpose. Whereas the crossmatch orig- 
inally had the dual purpose of providing final verification 
of ABO compatibility and detecting unexpected antibod- 
ies unrecognized by the antibody screening test, in the 
revised edition, the latter function was eliminated. This 
change was permitted by the demonstration of the rarity 
of detection of clinically significant unexpected antibod- 
ies, that were unrecognized by the antibody screening 
test, by a crossmatch that incorporated an antiglobulin 
t e ~ t . ~ - ~  Therefore, the fundamental purpose of the cross- 
match currently is to prevent potentially life-threatening 
acute hemolytic transfusion reactions due to the trans- 
fusion of ABO-incompatible red cells. 
Elimination of room-temperature incubation of the 
mixture of the patient’s serum with red cells from the 
donor unit, as well as of antiglobulin testing, resulted in 
the idiomatic expression “immediate-spin crossmatch.” 
It was acknowledged that there would be instances wherein 
weakly reactive antibodies, or antibodies against rare 
antigenic specificities, would be undetected by this pro- 
cedural modification, and yet these antibodies would be 
unlikely to result in significant patient morbidity. 
While the immediate-spin crossmatch is relied on for 
final confirmation of ABO compatibility, on rare occa- 
sion it has failed this mission. This has occurred because 
of the combination of a weak ABO antibody in the serum 
of a patient with donor red cells that represent an incom- 
patible subgroup of In even rarer instances, a false- 
negative immediate-spin crossmatch may result from a 
prozone phenomenon in tests incorporating very potent 
AT30 antibodies. This can be circumvented by suspend- 
ing the test red cells in EDTA.9 In addition, ABO in- 
compatibility will not be detected by the immediate-spin 
crossmatch in an infant with weak anti-A or anti-B that 
reacts only in the antiglobulin test. Transfusion of group 
0 red cells to such infants avoids that situation. It is 
conceivable that other patients with weakly reactive 
anti-A or anti-B may be unable to manifest in vitro ABO 
incompatibility. 
As was originally anticipated, there have been, during 
the past decade, isolated instances of unexpected anti- 
bodies that eluded detection until they were implicated 
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in hemolytic transfusion the reactions were 
usually of the delayed type, although none were fatal. 
The article by Pinkerton and his colleagues,” in this 
issue of TRANSFUSION, places this issue in proper 
perspective. It is particularly useful in that it separates 
those undetected antibodies that had clinical manifesta- 
tions from those that merely proved to be serologic an- 
noyances. The undetected antibodies that resulted in 
clinically evident delayed hemolytic transfusion reac- 
tions would not have been detected with more extensive 
pretransfusion testing. While the authors utilized a three- 
cell screening test, the important considerations are the 
representation of antigenic specificities on the screening 
cclls and the utilization of a test method that will allow 
the detection of the majority of clinically significant red 
cell antibodies, regardless of the number of test cells 
employed. 
In reviewing studies such as the one by Pinkerton and 
colleagues, one must take care to note the frequency of 
delayed hemolytic transfusion reactions. Patients with 
such reactions fail to have the desired hemoglobin in- 
crement following a transfusion and may require addi- 
tional transfusions, which subjects them to increased risk 
of posttransfusion disease. Only three such clinically 
manifest reactions occurred over 8 years in the Pinkerton 
study. While we may consider this to be an acceptably 
uncommon occurrence, what level of risk is unaccepta- 
ble to our patients? 
The immediate-spin crossmatch has facilitated the ability 
of transfusion services to respond to the demands of 
massive transfusions, especially for such surgical pro- 
cedures as liver transplantation or thoracoabdominal 
aneurysmectomy. In addition, it may be contended that 
enhanced speed of blood issuance resulting from the con- 
traction of pretransfusion testing has actually saved lives. 
Therefore, this has been another area of transfusion med- 
icine wherein the benefits of procedural revision had to 
be weighed against potential risk to the patient. Although 
there have been numerous affirmations of the proce- 
dure’s safety and benefits to patient care, many trans- 
fusion services continue to be reluctant to adopt it.13J4 
At this time, only testing to detect ABO incompati- 
bility is required of a major crossmatch before a trans- 
fusion is given to a patient who lacks or has lacked 
clinically significant unexpected antibodie~.’~ Recent ef- 
forts to abbreviate the procedure further, or even to elim- 
inate the serologic test, have stemmed from demands 
that blood banks contain costs while expediting the pro- 
vision of blood. However, these corresponding pressures 
must not be allowed to compromise patient care. It must 
be the responsibility of those primarily engaged in this 
subspecialty to be the guardians of this underlying 
requirement. 
While adoption of the immediate-spin crossmatch has 
been resisted by the majority of transfusion services in 
this country, further modification of the procedure is in 
the offing. The latest “spin” on complying with pre- 
transfusion test requirements in an expeditious manner 
utilizes computer The computer cross- 
match, or electronic crossmatch, may be inferred to be 
a logical extension of a concept introduced a decade ago, 
which linked the elimination of the crossmatch to veri- 
fication of the documentation of the testing that led to 
the determination of ,the ABO type and to the results in 
an extended antibody screening test.’* 
It is doubtful whether the saga of the revision of this 
procedure will cease at this point. The current cross- 
match only verifies work performed in the laboratory; 
however, provision of erroneous blood to the patient as 
a result of error on the patient-care unit continues to be 
the major cause of acute hemolytic transfusion reactions. 
Accordingly, the need continues for better verification 
of accuracy in all of the steps leading to the transfusion, 
beginning with the obtaining of the pretransfusion blood 
sample from the patient. Therefore, the crossmatch, in 
an expanded sense, should ensure the likelihood of op- 
timal survival of the transfused red cells in the appro- 
priate patient. 
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